Pharsight

Ferriprox patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8703156 CHIESI Liquid formulation for deferiprone with palatable taste
Oct, 2029

(6 years from now)

US10940115 CHIESI Delayed release deferiprone tablets and methods of using the same
Oct, 2038

(15 years from now)

US10780055 CHIESI Delayed release deferiprone tablets and methods of using the same
Oct, 2038

(15 years from now)

US10940116 CHIESI Delayed release deferiprone tablets and methods of using the same
Oct, 2038

(15 years from now)

US11357731 CHIESI Delayed release deferiprone tablets and methods of using the same
Oct, 2038

(15 years from now)

US11458103 CHIESI Delayed release deferiprone tablets and methods of using the same
Oct, 2038

(15 years from now)

Ferriprox is owned by Chiesi.

Ferriprox contains Deferiprone.

Ferriprox has a total of 6 drug patents out of which 0 drug patents have expired.

Ferriprox was authorised for market use on 09 September, 2015.

Ferriprox is available in solution;oral dosage forms.

Ferriprox can be used as method of treating transfusional iron overload.

The generics of Ferriprox are possible to be released after 25 October, 2038.

Drug Exclusivity Drug Exclusivity Expiration
New Indication (I) Apr 30, 2024
Orphan Drug Exclusivity (ODE) Apr 30, 2028

Drugs and Companies using DEFERIPRONE ingredient

Market Authorisation Date: 09 September, 2015

Treatment: Method of treating transfusional iron overload

Dosage: SOLUTION;ORAL

More Information on Dosage

FERRIPROX family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic